SCHEMBL24468601

SCHEMBL24468601

Nc1nc2ncc(C(=O)O)cc2c2c1COC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB1 P18505 2/20 0.35
GABRG2 P18507 2/20 0.35
GABRB3 P28472 2/20 0.35
GABRA5 P31644 2/20 0.35
GABRA3 P34903 2/20 0.35
GABRA2 P47869 2/20 0.35
GABRB2 P47870 2/20 0.35
GABRA4 P48169 2/20 0.35
GABRE P78334 2/20 0.35
GABRA6 Q16445 2/20 0.35
GABRG1 Q8N1C3 2/20 0.35
GABRG3 Q99928 2/20 0.35
GABRQ Q9UN88 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29650949 1.00 KDM4E (0.35) KDM4EALDH1A1MEN1KMT2AGABRP
SCHEMBL29106373 0.84 KDM4E (0.38) KDM4EALDH1A1MEN1KMT2AGABRP
SCHEMBL24468109 0.77 KDM4E (0.46) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL24468328 0.74 KEAP1 (0.39) KDM4EALDH1A1POLBHPGD
SCHEMBL24468603 0.72 KDM4E (0.35) KDM4EALDH1A1KMT2AGABRPGABRD
SCHEMBL29650940 0.72 KDM4E (0.35) KDM4EALDH1A1KMT2AGABRPGABRD
SCHEMBL23757875 0.71 GABRP (0.37) KDM4EALDH1A1MEN1KMT2AGABRP
SCHEMBL31253292 0.69 KDM4E (0.41) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL31712856 0.69 NNMT (0.40) LMNAPSMD14
Hydrochloric Acid SCHEMBL31461446 0.69 KDM4E (0.40) KDM4EALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124442-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS AMGEN INC. (US) 2024-04-18 US disclosed
US-20220194955-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-23 US disclosed
WO-2022132914-A1 PRMTS INHIBITORS AMGEN INC. (US) 2022-06-23 WO disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124442-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM4E 41/4885ALDH1A1 3736/4885MEN1 1049/4885
US-20220194955-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 KDM4E 36/4885ALDH1A1 2716/4885MEN1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.